Form 4: Minerva Neurosciences Director Acquires Stock Options

David Kupfer, a director at Minerva Neurosciences, acquired 12,500 stock options as part of the company's non-employee director compensation program.

Summary

• David Kupfer, a director at Minerva Neurosciences, was granted 12,500 stock options on December 5, 2024.
• These options were granted as part of the company's compensation program for non-employee directors.
• The options have an exercise price of $2.12 per share.
• The options vest in four equal quarterly installments, starting three months after December 5, 2024, and continuing every three months thereafter, contingent on continued service as a non-employee director.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns interests. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service by the director.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology industry to incentivize and retain board members.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across many industries, particularly in biotech.
• The vesting schedule of quarterly installments over a year is also a common approach to ensure continued service.
• The specific number of options granted and the exercise price are specific to Minerva Neurosciences and would need to be compared to similar companies to assess if they are in line with industry standards.

Stakeholder Impact

• The stock option grant has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director compensation, insider trading, Minerva Neurosciences, NERV, equity, vesting